Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Qiagen QIAstat-Dx Respiratory SARS-CoV-2 Panel

ASPR’s Portfolio of COVID-19 Medical Countermeasures under EUA

BARDA is supporting the development of Qiagen’s QIAstat-Dx Respiratory SARS-CoV-2 Panel to be added to the QIAstat-Dx Respiratory Panel. The device is used to run FDA-cleared tests for 21 respiratory pathogens. The device features easy-to-use molecular testing with novel workflows. The test kit can differentiate the SARS-CoV-2 coronavirus from other serious respiratory infections in patients who may have similar symptoms in a single testing run.  To learn more, see the award announcement.

Emergency Use Authorization

On April 30, 2020, FDA issued an Emergency Use Authorization (EUA) to allow Qiagen’s QIAstat-Dx Respiratory SARS-CoV-2 Panel to be used to diagnose COVID-19.  

  • This page last reviewed: May 21, 2020